Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 534

Sort by

Sort Order Select

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

Journal Articles

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Waleed Ghanima, MD PhD, Marc Michel, Abderrahim Khelif, Bernadette Darne, Pal André Holme, PhDMD

Blood (2019) 134 (Supplement_1): 2358.

https://doi.org/10.1182/blood-2019-126975

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome (WAS): Up to 8 Years of Follow up in 17 Subjects Treated Since 2010

Blood (2019) 134 (Supplement_1): 3346.

https://doi.org/10.1182/blood-2019-124665

Published: 2019

Journal Articles

Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration

Giang N. Nguyen, BS, John K. Everett, PhD, Hayley Raymond, BA, Samita Kafle, BS, Elizabeth P. Merricks, PhD, Haig H. Kazazian, MD, Timothy C. Nichols, MD, Frederic D. Bushman, PhD, Denise E. Sabatino, PhD

Blood (2019) 134 (Supplement_1): 611.

https://doi.org/10.1182/blood-2019-126007

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Amy Shapiro, Giancarlo Castaman, MD, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, MD, Silva Zupancic-Salek, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1139.

https://doi.org/10.1182/blood-2019-122809

Published: 2019

Journal Articles

Two Different Platelet Thresholds for Bleeding Prophylaxis in Children with Malignancies or Non-Malignant Disorders: The Bambino Gesù Children's Hospital Experience

Pierpaolo Berti, MD, Guglielmo Trua, MD, Francesco Lamura, MD, Laila Costantino, MD, Costantino Damico, MD, Alessandra Paoloni, MD, Maria Teresa Romano, MD, Katia Girardi, MD, Luisa Strocchio, MD, Elisabetta Cicchetti, Alessandra Bernardi, Valentina De Nava, Antonio Cappelli, Andrea Onetti Muda, MD PhD, Mauro Montanari, MD

Blood (2019) 134 (Supplement_1): 1173.

https://doi.org/10.1182/blood-2019-129132

Published: 2019

Journal Articles

VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD

Ferdows Atiq, Lisette M. Schütte, MD, Agnes E.M. Looijen, Bsc, Johan Boender, MD, Moniek P.M. de Maat, PhD, Marieke J.H.A. Kruip, MD PhD, Frank W.G. Leebeek, MD PhD

Blood (2019) 134 (Supplement_1): 1116.

https://doi.org/10.1182/blood-2019-123634

Published: 2019

Journal Articles

An Update on rFVIIa Use in Females with Rare Bleeding Disorders

Meera B. Chitlur, MD, Manuel Carcao, David Cooper, Shilpa Jain, Kaan Kavakli, Bryce Kerlin, Skye Peltier, Man-Chiu Poon, Hossam Saad, Amy Shapiro

Blood (2019) 134 (Supplement_1): 1119.

https://doi.org/10.1182/blood-2019-130298

Published: 2019

Journal Articles

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Paulette Bryant, MD, Jenny McDaniel, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 1126.

https://doi.org/10.1182/blood-2019-126659

Published: 2019

Journal Articles

Increased Platelet Force Is Associated with Decreased Bleeding Severity in Pediatric Immune Thrombocytopenia

Oluwamayokun T. Oshinowo, BS, Renee Copeland, BS, Christina Caruso, MD, Meredith E. Fay, BS, Traci Leong, PhD, Carolyn M. Bennett, MDMSc, Wilbur A. Lam, MD PhD, David R. Myers, PhD

Blood (2019) 134 (Supplement_1): 1096.

https://doi.org/10.1182/blood-2019-129573

Published: 2019

Journal Articles

Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database

Jonathan C. Roberts, Lynn M Malec, MD, Imrran Halari, Sarah Hale, Abiola Oladapo, Robert Sidonio

Blood (2019) 134 (Supplement_1): 2117.

https://doi.org/10.1182/blood-2019-122164

Published: 2019

Journal Articles

Thromboprophylaxis for Patients with Newly Diagnosed Vs. Recurrent Cancers: A Post-Hoc Analysis of the Avert Trial

Marina Atalla, James Zhang, MD, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD

Blood (2019) 134 (Supplement_1): 3660.

https://doi.org/10.1182/blood-2019-122970

Published: 2019

Journal Articles

Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire

Alexander Duncan, MD, Angela Kellum, PharmD, Shilpa Jain, Skye Peltier, Helen Smith, David Cooper, Hossam Saad

Blood (2019) 134 (Supplement_1): 3456.

https://doi.org/10.1182/blood-2019-128408

Published: 2019

Journal Articles

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Barbara A. Konkle, MD, Kimo Stine, MD, Nathan Visweshwar, MD, Thomas J. Harrington, MD, Andrew D. Leavitt, MD, Adam Giermasz, MD PhD, Steven Arkin, MD, Gregory Di Russo, MD, Ashley Snyder, PharmD, MPH, Adrian Woolfson, MD PhD, Didier Rouy, MD PhD

Blood (2019) 134 (Supplement_1): 2060.

https://doi.org/10.1182/blood-2019-122143

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome (WAS): Up to 8 Years of Follow up in 17 Subjects Treated Since 2010

Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Two Different Platelet Thresholds for Bleeding Prophylaxis in Children with Malignancies or Non-Malignant Disorders: The Bambino Gesù Children's Hospital Experience

VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD

An Update on rFVIIa Use in Females with Rare Bleeding Disorders

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Increased Platelet Force Is Associated with Decreased Bleeding Severity in Pediatric Immune Thrombocytopenia

Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database

Thromboprophylaxis for Patients with Newly Diagnosed Vs. Recurrent Cancers: A Post-Hoc Analysis of the Avert Trial

Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only